Lexicon Pharma (LXRX) Tops Q3 EPS by 7c, Miss on Revenues
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.24 -0.88%
EPS Growth %: -50.0%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
PMCB, CULP, HURC, More
EPS Growth %: -50.0%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.29), $0.07 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $26.94 million versus the consensus estimate of $27.96 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Guidewire Software (GWRE) Tops Q4 EPS by 6c; Offers Guidance
- Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
